This grant is for advancing drug repositioning and combination therapy development for Alzheimer’s Disease and Related Dementias (AD/ADRD). It aims to support rigorous preclinical testing using mouse models for drugs or drug combinations already in use for other conditions, or investigational drugs predicted to be effective against AD/ADRD. The initiative also encourages testing of these drug candidates in combination with non-pharmacologic interventions. The core purpose is to establish strong proof of concept, facilitating rational drug repurposing and the development of new combination therapies for the treatment and prevention of AD/ADRD, ultimately leading to robust translational outcomes.
Opportunity ID: 357943
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-25-374 |
| Funding Opportunity Title: | Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.866 — Aging Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Dec 30, 2024 |
| Last Updated Date: | Dec 30, 2024 |
| Original Closing Date for Applications: | May 07, 2028 |
| Current Closing Date for Applications: | May 07, 2028 |
| Archive Date: | Jun 12, 2028 |
| Estimated Total Program Funding: | $1,000,000 |
| Award Ceiling: | $1,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Private institutions of higher education Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled “Additional Information on Eligibility” for clarification) Public housing authorities/Indian housing authorities Independent school districts County governments Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Small businesses State governments Native American tribal governments (Federally recognized) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Notice of Funding Opportunity (NOFO) invites applications that propose to use mouse models to conduct rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in AD/ADRD. This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes. The central goal is to establish robust proof of concept that will enable rational drug repurposing and combination therapy development for the treatment and prevention of AD/ADRD. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-25-374.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 357943 Full Announcement-PAR-25-374 -> PAR-25-374-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-I | Use for due dates on or after January 25, 2025 | PKG00289839 | May 09, 2025 | May 07, 2028 | View |
Package 1
Mandatory forms
357943 RR_SF424_5_0-5.0.pdf
357943 PHS398_CoverPageSupplement_5_0-5.0.pdf
357943 RR_OtherProjectInfo_1_4-1.4.pdf
357943 PerformanceSite_4_0-4.0.pdf
357943 RR_KeyPersonExpanded_4_0-4.0.pdf
357943 PHS398_ResearchPlan_5_0-5.0.pdf
357943 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
357943 RR_Budget_3_0-3.0.pdf
357943 RR_SubawardBudget30_3_0-3.0.pdf
357943 PHS398_ModularBudget_1_2-1.2.pdf
357943 PHS_AssignmentRequestForm_4_0-4.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
